The vision of InteloMed is to bring actionable monitoring to hospital, outpatient and home settings across multiple clinical applications including hemodialysis, sleep- disturbed breathing, heart failure and medical/surgical.

Hemodialysis was selected for the first application and initial commercialization due to the significant need and the cardiovascular vulnerability of these patients. Each year, in the US alone, more than 400,000 people with kidney failure undergo more than 650 million dialysis treatments. While these treatments are life-saving, they create great stress on the cardiovascular system. More dialysis patients die from cardiovascular issues than their underlying kidney disease.